Is adjuvant radiotherapy warranted in resected pT1-2 node-positive rectal cancer?

Radiation Oncology

Sanjun Cai¹  Hongbin Wu¹  Debing Shi²  Ying Ding³  Xinxiang Li¹  Junjie Peng¹ 

[1] Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China;Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA

关键词: Prognosis;    Stage;    Local recurrence;    Radiotherapy;    Rectal cancer;   

Others  :  829469
DOI  :  10.1186/1748-717X-8-290

 received in 2013-07-25, accepted in 2013-12-15,  发布年份 2013

【 摘 要 】

Background

Stage T1-2 rectal cancers are unlikely to have lymph node metastases and neoadjuvant therapy is not routinely administered. Postoperative management is controversial if lymph node metastases are detected in the resected specimen. We studied the outcomes of patients with pT1-2 node-positive rectal cancer in order to determine whether adjuvant radiotherapy was beneficial.

Methods

We conducted a retrospective analysis of 284 patients with pathological T1-2 node-positive rectal cancer from a single institution. Outcomes, including local recurrence (LR), distant metastasis (DM), disease free survival (DFS) and overall survival (OS), were studied in patients with detailed TN staging and different adjuvant treatment modalities.

Results

The overall 5-year LR, DM, DFS and OS rates for all patients were 12.5%, 32.9%, 36.4% and 76.8%, respectively. Local control was inferior among patients who received no adjuvant therapy. Patients could be divided into three risk subsets: Low-risk, T1N1; Intermediate-risk, T2N1 and T1N2; and High-risk, T2N2. The 5-year LR rates were 5.3%, 9.8% and 26.4%, respectively (p = 0.005). In High-risk patients, addition of radiotherapy achieved a 5-year LR rate of 9.1%, compared 34.8% without radiotherapy.

Conclusions

In our study, we provide the detailed outcomes and preliminary survival analysis in a relatively infrequent subset of rectal cancer. Three risk subsets could be identified based on local control for pT1-2 node positive rectal cancer. Postoperative treatment needs to be individualized for patients with pT1-2 node-positive rectal cancer.

【 授权许可】

   
2013 Peng et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Sauer R, Becker H, Hohenberger W, et al.: Preoperative versus postoperative chemoradiotherapy for rectal cancer. New Engl J Med 2004, 351:1731-1740.
• [2]Bosset JF, Collette L, Calais G, et al.: Chemotherapy with preoperative radiotherapy in rectal cancer. New Engl J Med 2006, 355:1114-1123.
• [3]Roh MS, Colangelo LH, O’Connell MJ, et al.: Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol: Off J Am Soc Clin Oncol 2009, 27:5124-5130.
• [4]Gunderson LL, Sargent DJ, Tepper JE, et al.: Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol, Biol, Phys 2002, 54:386-396.
• [5]Chok KS, Law WL: Prognostic factors affecting survival and recurrence of patients with pT1 and pT2 colorectal cancer. World J Surg 2007, 31:1485-1490.
• [6]Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG (Eds): MM. AJCC Cancer Staging Manual. 6th edition. New York: Springer-Verlag; 2002.
• [7]Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds): AJCC Cancer Staging Manual. 7th edition. New York: Springer; 2010.
• [8]NIH consensus conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA: J Am Med Assoc 1990, 264:1444-1450.
• [9]Akasu T, Kondo H, Moriya Y, et al.: Endorectal ultrasonography and treatment of early stage rectal cancer. World J Surg 2000, 24:1061-1068.
• [10]Brown G, Davies S, Williams GT, et al.: Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? Br J Cancer 2004, 91:23-29.
• [11]Panzironi G, De Vargas MM, Manganaro L, et al.: Preoperative locoregional staging of rectal carcinoma: comparison of MR, TRUS and multislice CT. Personal experience. La Radiol Med 2004, 107:344-355.
• [12]Al-Sukhni E, Milot L, Fruitman M, et al.: Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: A systematic review and meta-analysis. Ann Surg Oncol 2012, 19:2212-2223.
• [13]Gagliardi G, Bayar S, Smith R, Salem RR: Preoperative staging of rectal cancer using magnetic resonance imaging with external phase-arrayed coils. Arch Surg 2002, 137:447-451.
• [14]Bentrem DJ, Okabe S, Wong WD, et al.: T1 adenocarcinoma of the rectum: transanal excision or radical surgery? Ann Surg 2005, 242:472-477. discussion 477–479
• [15]Peng J, Chen W, Venook AP, et al.: Long-term outcome of early-stage rectal cancer undergoing standard resection and local excision. Clin Colorectal Cancer 2011, 10:37-41.
• [16]Peng J, Chen W, Sheng W, et al.: Oncological outcome of T1 rectal cancer undergoing standard resection and local excision. Colorectal Dis: Off J Assoc Coloproctology G B Irel 2011, 13:e14-e19.
• [17]Brodsky JT, Richard GK, Cohen AM, Minsky BD: Variables correlated with the risk of lymph node metastasis in early rectal cancer. Cancer 1992, 69:322-326.
• [18]Nascimbeni R, Burgart LJ, Nivatvongs S, Larson DR: Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. 2002, 45:200-206. [Diseases of the colon and rectum]
• [19]Andre T, Boni C, Navarro M, et al.: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol: Off J Am Soc Clin Oncol 2009, 27:3109-3116.
• [20]Twelves C, Wong A, Nowacki MP, et al.: Capecitabine as adjuvant treatment for stage III colon cancer. New Engl J Med 2005, 352:2696-2704.
• [21]Law WL, Chu KW: Anterior resection for rectal cancer with mesorectal excision: A prospective evaluation of 622 patients. Ann Surg 2004, 240:260-268.
• [22]Law WL, Chu KW: Local recurrence following total mesorectal excision with double-stapling anastomosis for rectal cancers: Analysis of risk factors. World J Surg 2002, 26:1272-1276.
• [23]Moore E, Heald RJ, Cecil TD, Sharpe GD, Sexton R, Moran BJ: Almost all five year disease free survivors are cured following rectal cancer surgery, but longer term follow-up detects some late local and systemic recurrences. Colorectal Dis: Off J Assoc Coloproctology G B Irel 2005, 7:403-405.
• [24]Krook JE, Moertel CG, Gunderson LL, et al.: Effective surgical adjuvant therapy for high-risk rectal carcinoma. New Engl J Med 1991, 324:709-715.
• [25]O’Connell MJ, Martenson JA, Wieand HS, et al.: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. New Engl J Med 1994, 331:502-507.
• [26]Tepper JE, O’Connell MJ, Petroni GR, et al.: Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol: Off J Am Soc Clin Oncol 1997, 15:2030-2039.
• [27]Wolmark N, Wieand HS, Hyams DM, et al.: Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National surgical adjuvant breast and bowel project protocol R-02. J Natl Cancer Inst 2000, 92:388-396.
• [28]Gunderson LL, Sargent DJ, Tepper JE, et al.: Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: A pooled analysis. J Clin Oncol: Off J Am Soc Clin Oncol 2004, 22:1785-1796.
• [29]Rasheed S, Bowley DM, Aziz O, et al.: Can depth of tumour invasion predict lymph node positivity in patients undergoing resection for early rectal cancer? A comparative study between T1 and T2 cancers. Colorectal Dis: Off J Assoc Coloproctology G B Irel 2008, 10:231-238.
• [30]Bayar S, Saxena R, Emir B, Salem RR: Venous invasion may predict lymph node metastasis in early rectal cancer. Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol 2002, 28:413-417.
• [31]Fang WL, Chang SC, Lin JK, et al.: Metastatic potential in T1 and T2 colorectal cancer. Hepato-gastroenterol 2005, 52:1688-1691.